1. Development or worsening of sarcoidosis associated with IL‐17 blockade for psoriasis. (19th May 2020) Authors: Hornick, N.; Wang, A.; Lim, Y.; Gehlhausen, J.; Siegel, J.; Wang, J.; Foss, F.; Lim, I.; Zubek, A.; Milstone, L.; Galan, A.; King, B.; Damsky, W. Journal: Journal of the European Academy of Dermatology and Venereology Issue: Volume 34:Number 10(2020) Page Start: e583 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Efficacy and safety of mogamulizumab by patient baseline blood tumour burden: a post hoc analysis of the MAVORIC trial. (20th August 2021) Authors: Cowan, R.A.; Scarisbrick, J.J.; Zinzani, P.L.; Nicolay, J.P.; Sokol, L.; Pinter‐Brown, L.; Quaglino, P.; Iversen, L.; Dummer, R.; Musiek, A.; Foss, F.; Ito, T.; Rosen, J‐P.; Medley, M.C. Journal: Journal of the European Academy of Dermatology and Venereology Issue: Volume 35:Number 11(2021) Page Start: 2225 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Interleukin‐17 blockade downregulates NOD2 in skin and may promote paradoxical sarcoidosis. (6th May 2020) Authors: Wang, A.; Hornick, N.; Lim, Y.; Gehlhausen, J.; Siegel, J.; Wang, J.; Foss, F.; Lim, I.; Zubek, A.; Milstone, L.; Galan, A.; King, B.; Damsky, W. Journal: Journal of the European Academy of Dermatology and Venereology Issue: Volume 34:Number 9(2020) Page Start: e497 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. PRELIMINARY RESULTS OF ASTX660, A NOVEL NON‐PEPTIDOMIMETIC cIAP1/2 AND XIAP ANTAGONIST, IN RELAPSED/REFRACTORY PERIPHERAL T‐CELL LYMPHOMA AND CUTANEOUS T CELL LYMPHOMA. (12th June 2019) Authors: Samaniego, F.; Hollebecque, A.; Foss, F.; Lister, J.; Mita, M.; Wagner‐Johnston, N.; Dyer, M.; You, B.; Prica, A.; Hernandez‐Llizaliturri, F.; Ferraldeschi, R.; Chan, D.; Zhang, J.; Mehta, A. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 527 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. S217: PRELIMINARY ANALYSIS OF THE PHASE II STUDY USING TOLINAPANT (ASTX660) MONOTHERAPY IN 98 PERIPHERAL T-CELL LYMPHOMA AND 51 CUTANEOUS T-CELL LYMPHOMA SUBJECTS WITH RELAPSED REFRACTORY DISEASE. (23rd June 2022) Authors: Michot, J.-M.; Mehta, A.; Samaniego, F.; Bachy, E.; Zinzani, P. L.; Prica, A.; Colins, G. P.; Ribrag, V; Wagner-Johnston, N.; El-Sharkawi, D.; O'Connor, O. A.; Wilcox, R.; Wang, L.; Wilson, L.; Sims, M.; Taylor, J. A.; Keer, H. N.; Foss, F. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 118 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. TIPIFARNIB IN RELAPSED OR REFRACTORY ANGIOIMMUNOBLASTIC T‐CELL LYMPHOMA (AITL) AND CXCL12+ PERIPHERAL T‐CELL LYMPHOMA (PTCL): PRELIMINARY RESULTS FROM A PHASE 2 STUDY. (12th June 2019) Authors: Witzig, T.; Sokol, L.; Kim, W.; Foss, F.; Jacobsen, E.; de la Cruz Vincente, F.; Caballero, D.; Advani, R.; Roncero Vidal, J.M.; Marin‐Niebla, A.; Rodriguez Izquierdo, A.; de Ona Navarrete, R.; Terol, M.J.; Domingo‐Domenech, E.; Rodriguez, M.; Piris, M.A.; Bolognese, J.; Janes, M.R.; Burrows, F.;... Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 64 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗